1. Estes, C., et al. (2018). Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology (Baltimore, Md.)67(1), 123–133.


  1. Harrison, S. A., et al. (2021). Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. Journal of hepatology75(2), 284–291.


  1. Schaapman, J. J., Tushuizen, M. E., Coenraad, M. J., & Lamb, H. J. (2021). Multiparametric MRI in Patients With Nonalcoholic Fatty Liver Disease. Journal of magnetic resonance imaging: JMRI53(6), 1623–1631.


  1. Wood, J. C., et al. (2005). MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood, 106(4), 1460–1465.


  1. Hoad, C. L., et al. (2015). A study of T₁ relaxation time as a measure of liver fibrosis and the influence of confounding histological factors. NMR in biomedicine28(6), 706–714.


  1. Banerjee, R., et al. (2014). Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. Journal of Hepatology, 60(1), 69-77.


  1. Pavlides, , et al. (2017). Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity. Liver International, 37(7), 1065-1073.


  1. Harrison, S. A., et al. (2018). Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial. PloS one13(9), e0203054.


  1. Bachtiar, V., et al. (2019). Repeatability and reproducibility of multiparametric magnetic resonance imaging of the liver. PLoS One, 14(4), e0214921.


  1. Pavlides, M., et al. (2016). Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. Journal of hepatology64(2), 308–315.


  1. Jayaswal, A., et al. (2020). Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood-based fibrosis markers in patients with chronic liver disease. Liver International, 40(12), 3071-3082.


  1. Imajo, K., et al. (2021). Quantitative multiparametric MRI can aid NASH diagnosis in a Japanese cohort. World Journal of Gastroenterology, 27(7), 609–623.


  1. Andersson, A., et al. (2021). Clinical utility of MRI biomarkers for identifying NASH patients at high risk of progression: A multi-center pooled data and meta-analysis. Clinical Gastroenterology and Hepatology. Advance online publication.


  1. Dennis, A., et al. (2021). Correlations between MRI biomarkers PDFF and cT1 with histopathological features of non-alcoholic steatohepatitis. Frontiers in Endocrinology, 11, 575843.


  1. Beyer, C., et al. (2021). Comparison between magnetic resonance and ultrasound-derived indicators of hepatic steatosis in a pooled NAFLD cohort. PloS one16(4), e0249491.


  1. Harrison, S. A., et al. (2020). NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis. Hepatology (Baltimore, Md.)71(4), 1198–1212.


  1. Harrison, S. A., et al. (2021). Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease. The American journal of gastroenterology116(12), 2399–2409.